Kiniksa Pharmaceuticals International (KNSA)
Market Price (3/1/2026): $44.55 | Market Cap: $3.3 BilSector: Health Care | Industry: Pharmaceuticals
Kiniksa Pharmaceuticals International (KNSA)
Market Price (3/1/2026): $44.55Market Cap: $3.3 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 87x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 32x, P/EPrice/Earnings or Price/(Net Income) is 93x |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 56% | Stock price has recently run up significantly12M Rtn12 month market price return is 119% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3% |
| Low stock price volatilityVol 12M is 44% | Key risksKNSA key risks include [1] a significant overreliance on its lead therapy, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 56% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Low stock price volatilityVol 12M is 44% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 87x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 32x, P/EPrice/Earnings or Price/(Net Income) is 93x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 119% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3% |
| Key risksKNSA key risks include [1] a significant overreliance on its lead therapy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Strong Performance and Optimistic Guidance for ARCALYST Revenue.
Kiniksa Pharmaceuticals reported robust financial results for ARCALYST, with net product revenue reaching $202.1 million in the fourth quarter of 2025 and $677.6 million for the full year 2025, representing a 62% year-over-year increase. The company projects continued growth, expecting 2026 ARCALYST net product revenue to be between $900 million and $920 million, signaling strong commercial momentum.
2. Transition to Net Profitability and Enhanced Financial Strength.
The company demonstrated a significant financial turnaround, achieving a net income of $14.2 million in the fourth quarter of 2025, a notable improvement from a net loss in the same period of 2024. For the full year 2025, Kiniksa reported a net income of $59.0 million, reversing a net loss of $43.2 million in 2024. This shift to profitability, driven by higher collaboration profit margins and disciplined operations, contributed to a substantial increase in cash and equivalents by $170.4 million in 2025, reaching $414.1 million as of December 31, 2025.
Show more
Stock Movement Drivers
Fundamental Drivers
The 4.6% change in KNSA stock from 11/30/2025 to 2/28/2026 was primarily driven by a 4.6% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 2282026 | Change |
|---|---|---|---|
| Stock Price ($) | 42.52 | 44.49 | 4.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 598 | 598 | 0.0% |
| Net Income Margin (%) | 6.0% | 6.0% | 0.0% |
| P/E Multiple | 88.4 | 92.5 | 4.6% |
| Shares Outstanding (Mil) | 75 | 75 | 0.0% |
| Cumulative Contribution | 4.6% |
Market Drivers
11/30/2025 to 2/28/2026| Return | Correlation | |
|---|---|---|
| KNSA | 4.6% | |
| Market (SPY) | 0.4% | -1.4% |
| Sector (XLV) | 1.6% | 16.9% |
Fundamental Drivers
The 32.8% change in KNSA stock from 8/31/2025 to 2/28/2026 was primarily driven by a 563.8% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 2282026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.49 | 44.49 | 32.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 529 | 598 | 13.0% |
| Net Income Margin (%) | 0.9% | 6.0% | 563.8% |
| P/E Multiple | 513.5 | 92.5 | -82.0% |
| Shares Outstanding (Mil) | 73 | 75 | -1.7% |
| Cumulative Contribution | 32.8% |
Market Drivers
8/31/2025 to 2/28/2026| Return | Correlation | |
|---|---|---|
| KNSA | 32.8% | |
| Market (SPY) | 6.6% | 10.2% |
| Sector (XLV) | 17.1% | 27.5% |
Fundamental Drivers
The 119.4% change in KNSA stock from 2/28/2025 to 2/28/2026 was primarily driven by a 60.4% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 2282026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.28 | 44.49 | 119.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 423 | 598 | 41.3% |
| P/S Multiple | 3.5 | 5.6 | 60.4% |
| Shares Outstanding (Mil) | 72 | 75 | -3.2% |
| Cumulative Contribution | 119.4% |
Market Drivers
2/28/2025 to 2/28/2026| Return | Correlation | |
|---|---|---|
| KNSA | 119.4% | |
| Market (SPY) | 16.5% | 19.9% |
| Sector (XLV) | 9.0% | 26.8% |
Fundamental Drivers
The 246.0% change in KNSA stock from 2/28/2023 to 2/28/2026 was primarily driven by a 1377.4% change in the company's P/E Multiple.| (LTM values as of) | 2282023 | 2282026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.86 | 44.49 | 246.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 177 | 598 | 237.8% |
| Net Income Margin (%) | 80.5% | 6.0% | -92.5% |
| P/E Multiple | 6.3 | 92.5 | 1377.4% |
| Shares Outstanding (Mil) | 69 | 75 | -7.1% |
| Cumulative Contribution | 246.0% |
Market Drivers
2/28/2023 to 2/28/2026| Return | Correlation | |
|---|---|---|
| KNSA | 246.0% | |
| Market (SPY) | 79.6% | 21.0% |
| Sector (XLV) | 31.8% | 22.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| KNSA Return | -33% | 27% | 17% | 13% | 109% | 5% | 146% |
| Peers Return | 20% | 20% | 1% | 6% | 22% | 10% | 105% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% |
Monthly Win Rates [3] | |||||||
| KNSA Win Rate | 50% | 42% | 50% | 42% | 75% | 50% | |
| Peers Win Rate | 55% | 57% | 47% | 60% | 58% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| KNSA Max Drawdown | -41% | -35% | -30% | -4% | -8% | -8% | |
| Peers Max Drawdown | -7% | -7% | -16% | -14% | -12% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: REGN, AMGN, ABBV, BMY, GILD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/27/2026 (YTD)
How Low Can It Go
| Event | KNSA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -68.3% | -25.4% |
| % Gain to Breakeven | 215.4% | 34.1% |
| Time to Breakeven | 783 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -44.3% | -33.9% |
| % Gain to Breakeven | 79.6% | 51.3% |
| Time to Breakeven | 34 days | 148 days |
| 2018 Correction | ||
| % Loss | -83.1% | -19.8% |
| % Gain to Breakeven | 490.3% | 24.7% |
| Time to Breakeven | 2,114 days | 120 days |
Compare to REGN, AMGN, ABBV, BMY, GILD
In The Past
Kiniksa Pharmaceuticals International's stock fell -68.3% during the 2022 Inflation Shock from a high on 2/19/2021. A -68.3% loss requires a 215.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Kiniksa Pharmaceuticals International (KNSA)
AI Analysis | Feedback
1. Alexion Pharmaceuticals for rare inflammatory diseases, but on a smaller scale.
2. A specialized biotech company akin to Vertex Pharmaceuticals, focused on autoimmune and inflammatory rare diseases.
AI Analysis | Feedback
- ARCALYST (rilonacept): An interleukin-1 (IL-1) blocker approved for treating recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of IL-1 Receptor Antagonist (DIRA).
- Vixarelimab: A fully human monoclonal antibody in clinical development designed to inhibit oncostatin M (OSM) for the potential treatment of prurigo nodularis and other inflammatory diseases.
- KPL-404: A monoclonal antibody in clinical development that targets the CD40 ligand (CD40L) for the potential treatment of various autoimmune diseases.
AI Analysis | Feedback
Kiniksa Pharmaceuticals International (KNSA) sells primarily to other companies within the pharmaceutical supply chain, not directly to individuals. According to Kiniksa's latest Annual Report on Form 10-K for the year ended December 31, 2023, the company's major customers are primarily **specialty distributors** and **specialty pharmacies** in the United States. Kiniksa's 10-K filing explicitly states a significant customer concentration: "For the years ended December 31, 2023, 2022 and 2021, **two customers accounted for 90%, 88% and 88% of our net product revenue, respectively.**" However, Kiniksa Pharmaceuticals International does not publicly disclose the specific names of these two major customers in its SEC filings or other public investor communications. Therefore, while the company relies heavily on two specific entities, their names are not identified by KNSA. Based on the publicly available information, the categories of customers that KNSA serves are:- Specialty Distributors: These companies handle the distribution of complex, high-cost, and often temperature-sensitive pharmaceutical products like those developed by Kiniksa. They serve as intermediaries between the pharmaceutical manufacturer and the dispensing pharmacies or healthcare providers.
- Specialty Pharmacies: These pharmacies focus on dispensing and managing specialty medications, which often require special handling, administration, and patient education. They provide comprehensive support to patients taking these complex drugs.
AI Analysis | Feedback
null
AI Analysis | Feedback
Kiniksa Pharmaceuticals International (KNSA)Sanj K. Patel, CEO & Chairman of the Board
Sanj K. Patel is the CEO and Chairman of the Board of Kiniksa Pharmaceuticals, which he took public on the NASDAQ Global Market in May 2018. He brings over 30 years of experience in the biopharmaceutical industry. Prior to founding Kiniksa, Mr. Patel founded Synageva BioPharma in 2008, where he designed and initiated its lead program, Kanuma®, for lysosomal acid lipase deficiency. He took Synageva public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital. In June 2015, Synageva was sold to Alexion Pharmaceuticals for $9.7 billion, which was noted as the highest premium ever paid for a biotech company valued over $5 billion. Before Synageva, Mr. Patel spent almost a decade as an executive at Genzyme Corporation, holding senior leadership roles in sales, marketing, and clinical research, and was instrumental in the commercialization of several treatments, including leading the Fabrazyme® clinical operations team to FDA approval.
Mark Ragosa, Executive Vice President, Chief Financial Officer
Mark Ragosa joined Kiniksa in 2018 and became Chief Financial Officer in 2021, overseeing finance, investor relations, corporate communications, human resources, quality, and information technology functions. He has over 25 years of experience in the financial services and biopharmaceutical industries. Prior to joining Kiniksa, he was a member of the investor relations team at Ironwood Pharmaceuticals. Earlier in his career, Mr. Ragosa held roles of increasing responsibility within the equities divisions of Goldman Sachs, Morgan Stanley, and Bank of America Securities, where he facilitated capital raises for private and public companies and conducted financial analyses. He is a Chartered Financial Analyst.
Ross Moat, Executive Vice President, Chief Corporate & Commercial Officer
Ross Moat joined Kiniksa in 2019 and serves as Executive Vice President, Chief Corporate & Commercial Officer, bringing over 22 years of experience in biopharmaceuticals. He has led sales, marketing, commercial operations, market access, and diagnostic functions within orphan and ultra-orphan disease fields. Before Kiniksa, Mr. Moat played a lead role in the successful commercialization efforts for innovative gene therapies at Novartis Gene Therapies and Spark Therapeutics. He also served as the metabolic franchise commercial head at Alexion following its acquisition of Synageva, where he was previously General Manager for the UK & Ireland.
Eben Tessari, Executive Vice President, Chief Operating Officer
Eben Tessari joined Kiniksa at its founding in 2015. He was initially Chief Business Officer, overseeing long-range strategic planning, forecasting, decision analysis, business development, licensing, valuation, and new product strategy. In January 2022, he was promoted to Chief Operating Officer, where he oversees functional leadership teams in business development, program management, clinical development, manufacturing, and research. Before Kiniksa, he was Senior Director and Head of Business Development at Synageva BioPharma.
Dr. John F. Paolini, M.D., Executive Vice President and Chief Medical Officer
Dr. John F. Paolini serves as the Executive Vice President and Chief Medical Officer at Kiniksa Pharmaceuticals. His role involves guiding the clinical development of the company's therapies.
AI Analysis | Feedback
Kiniksa Pharmaceuticals International (KNSA) faces several key risks inherent to the biopharmaceutical industry. The most significant risks include:1. Dependence on Key Product Candidates and Overreliance on Arcalyst
Kiniksa Pharmaceuticals International is notably dependent on a limited number of product candidates, particularly its lead therapy, Arcalyst. This reliance poses a significant risk, as any setbacks in clinical trials, regulatory approvals, or the emergence of competitive or regulatory pressures concerning Arcalyst could materially impact the company's revenue streams and future prospects. While strong sales of Arcalyst have contributed to recent financial performance, limited diversification means that any adverse changes in Arcalyst's competitive or regulatory environment could quickly affect revenue and earnings growth.
2. Regulatory and Development Risks
The path to bringing new pharmaceuticals to market is fraught with complex regulatory hurdles and development risks. Kiniksa must navigate intricate approval processes and potential delays, which could impact its ability to capitalize on its product pipeline. Risks include delays or difficulties in patient enrollment for clinical trials, challenges in completing trials as originally designed, and the potential for regulatory authorities to delay or deny approval of product candidates or require additional data. The need for continuous investment in research to stay ahead in the fast-paced industry can also strain financial resources.
3. Competitive Market Pressures
The biopharmaceutical industry is highly competitive, with numerous players vying for market share. Kiniksa Pharmaceuticals International faces the ongoing challenge of maintaining its competitive edge amidst rapid technological advancements and aggressive market strategies from competitors. Increased competition could intensify for Arcalyst, potentially affecting its market penetration and pricing power. Sustaining growth and market position necessitates continuous innovation and strategic partnerships.
AI Analysis | Feedback
The ongoing Phase 3 clinical development of AbbVie's Rinvoq (upadacitinib) for Giant Cell Arteritis (GCA) presents a clear emerging threat. Rinvoq is an oral JAK inhibitor that, if approved, would compete directly in a market that Kiniksa is targeting with its investigational anti-GM-CSF receptor antibody, mavrilimumab. The potential approval of a highly effective oral therapy like Rinvoq could significantly impact the market potential and commercial viability of mavrilimumab in GCA.
AI Analysis | Feedback
Kiniksa Pharmaceuticals International (KNSA) focuses on developing and commercializing therapeutic medicines for debilitating diseases with significant unmet medical needs. Their main products and pipeline candidates, along with their addressable markets, are as follows:
-
ARCALYST (rilonacept): Approved for recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) in the U.S..
- For **recurrent pericarditis**, the target addressable market in the U.S. is estimated to be 14,000 multiple-recurrence patients.
- The global recurrent pericarditis market is estimated to be valued at approximately USD 585.63 billion in 2025 and is projected to reach USD 851.90 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2032.
- The pericarditis drugs market (which includes recurrent pericarditis) in the U.S. reached USD 1.8 billion in 2024. The global pericarditis market size was estimated at USD 2.32 billion in 2024 and is expected to grow to USD 3.37 billion in 2029, at a CAGR of 7.9%. The recurrent pericarditis segment specifically is anticipated to grow at a CAGR of 6.6%.
- KPL-387 (investigational): This is an investigational human immunoglobulin G2 monoclonal antibody in a Phase 2/3 clinical trial for advanced recurrent pericarditis. KPL-387 is intended to further expand the IL-1 inhibition market for recurrent pericarditis.
-
Mavrilimumab (previously in pipeline): While mavrilimumab was previously in development for Giant Cell Arteritis (GCA), Kiniksa has discontinued its development for this indication.
- For **Giant Cell Arteritis**, the estimated U.S. prevalence is approximately 75,000 – 150,000 patients.
- The global Giant Cell Arteritis Therapeutics Market was valued at approximately USD 1.14 billion in 2024 and is projected to reach nearly USD 1.82 billion by 2032, with a CAGR of 6% from 2025 to 2032.
- Across the top 7 markets (US, EU4, UK, and Japan), the giant cell arteritis market reached USD 1,180.4 million in 2024 and is expected to reach USD 1,945.5 million by 2035.
-
Vixarelimab (licensed out): Kiniksa has entered a global license agreement with Roche and Genentech for the development and commercialization of vixarelimab.
- It was being evaluated for **prurigo nodularis**, a chronic inflammatory skin condition with an estimated U.S. prevalence of approximately 300,000 patients.
-
KPL-404 (investigational): In Phase 2 clinical trials for **rheumatoid arthritis**.
- The broader global tumor necrosis factor (TNF) inhibitor drugs market, which includes treatments for rheumatoid arthritis, was valued at USD 41.3 billion in 2023 and is projected to reach USD 51.55 billion by 2034, growing at a CAGR of 1.86% from 2025 to 2034. North America holds the largest share of this market.
AI Analysis | Feedback
Kiniksa Pharmaceuticals International (KNSA) is anticipated to experience future revenue growth over the next 2-3 years, driven by several key factors:
-
Continued Expansion of ARCALYST Market Penetration: The primary driver for Kiniksa's near-term revenue growth is the ongoing expansion of ARCALYST's (rilonacept) market penetration for recurrent pericarditis. The company has consistently raised its 2025 net sales guidance for ARCALYST, projecting it to be between $670 million and $675 million. This growth is fueled by an increasing number of active commercial patients, a growing prescriber base, and a longer average duration of therapy. As of late 2024/mid-2025, only approximately 13-15% of the estimated 14,000 multiple-recurrence patients were on ARCALYST therapy, indicating significant room for further adoption.
-
Favorable Evolution of Treatment Guidelines for Recurrent Pericarditis: There is a notable shift in clinical guidelines towards earlier and more frequent use of IL-1 pathway inhibition, which ARCALYST addresses, as a steroid-sparing approach for recurrent pericarditis. This evolving standard of care supports broader and earlier adoption of ARCALYST, contributing to sustained revenue momentum.
-
Potential Commercialization of KPL-387 in Recurrent Pericarditis: Kiniksa's pipeline asset, KPL-387, which has received Orphan Drug Designation from the FDA for pericarditis, is expected to be a significant future growth driver. KPL-387 aims to offer an improved dosing regimen with a target profile of monthly subcutaneous injection in a liquid formulation, potentially enhancing patient convenience and further expanding the recurrent pericarditis market. Data from its Phase 2 dose-focusing trial is anticipated in the second half of 2026. Additionally, KPL-387 and KPL-1161 (another next-generation IL-1 monoclonal antibody) are wholly owned by Kiniksa, meaning the company would retain all profits, unlike ARCALYST, which is subject to profit-sharing.
-
Advancement of Other Pipeline Assets: Beyond ARCALYST and KPL-387, Kiniksa's broader pipeline, including KPL-1161 for recurrent pericarditis (with a target of quarterly dosing) and Vixarelimab for prurigo nodularis (currently in Phase 2b clinical trials), represents opportunities for revenue diversification. Successful development and potential commercialization of these assets would reduce reliance on a single product and provide additional revenue streams in the mid to long term.
AI Analysis | Feedback
```html[2] Share Issuance
- In July 2020, Kiniksa Pharmaceuticals priced a public offering of 5,952,381 Class A common shares at $21.00 per share.
- Concurrently in July 2020, the company conducted a private placement of 1,428,572 Class A1 common shares.
- The gross proceeds from both the public offering and concurrent private placement were approximately $155.0 million.
[4] Outbound Investments
- In February 2025, Kiniksa announced the discontinuation of the development of abiprubart in Sjögren's Disease, signaling a reallocation of capital.
- Also in February 2025, the company terminated its exclusive license agreement for mavrilimumab with MedImmune.
[5] Capital Expenditures
- For the last 12 months as of November 7, 2025, capital expenditures were approximately -$1.13 million.
- Kiniksa expects to remain cash flow positive on an annual basis and continue investing across its business, including commercialization and pipeline advancement.
Latest Trefis Analyses
Trade Ideas
Select ideas related to KNSA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 190.51 |
| Mkt Cap | 155.9 |
| Rev LTM | 33,096 |
| Op Inc LTM | 10,390 |
| FCF LTM | 8,778 |
| FCF 3Y Avg | 8,839 |
| CFO LTM | 9,988 |
| CFO 3Y Avg | 9,795 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.5% |
| Rev Chg 3Y Avg | 4.1% |
| Rev Chg Q | 6.6% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Mgn LTM | 27.1% |
| Op Mgn 3Y Avg | 25.6% |
| QoQ Delta Op Mgn LTM | 2.9% |
| CFO/Rev LTM | 30.2% |
| CFO/Rev 3Y Avg | 32.1% |
| FCF/Rev LTM | 26.5% |
| FCF/Rev 3Y Avg | 27.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 155.9 |
| P/S | 5.7 |
| P/EBIT | 17.4 |
| P/E | 24.4 |
| P/CFO | 19.7 |
| Total Yield | 6.1% |
| Dividend Yield | 2.3% |
| FCF Yield 3Y Avg | 5.8% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.0% |
| 3M Rtn | 8.9% |
| 6M Rtn | 34.3% |
| 12M Rtn | 22.4% |
| 3Y Rtn | 73.6% |
| 1M Excs Rtn | 7.8% |
| 3M Excs Rtn | 7.7% |
| 6M Excs Rtn | 26.9% |
| 12M Excs Rtn | 8.9% |
| 3Y Excs Rtn | 3.8% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA125249 | ARCALYST | rilonacept | vial | 2272008 | |||||
Price Behavior
| Market Price | $44.49 | |
| Market Cap ($ Bil) | 3.3 | |
| First Trading Date | 05/24/2018 | |
| Distance from 52W High | -6.9% | |
| 50 Days | 200 Days | |
| DMA Price | $42.95 | $36.25 |
| DMA Trend | up | up |
| Distance from DMA | 3.6% | 22.7% |
| 3M | 1YR | |
| Volatility | 38.1% | 44.2% |
| Downside Capture | 24.96 | -1.30 |
| Upside Capture | 53.44 | 79.37 |
| Correlation (SPY) | 1.6% | 20.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.02 | -0.11 | 0.02 | 0.28 | 0.46 | 0.67 |
| Up Beta | -0.42 | 0.51 | 0.45 | 0.88 | 0.37 | 0.58 |
| Down Beta | 1.96 | -0.81 | -1.04 | -0.33 | 0.72 | 0.80 |
| Up Capture | -28% | 38% | 52% | 74% | 70% | 60% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 14 | 25 | 34 | 69 | 137 | 388 |
| Down Capture | -66% | -36% | 26% | 2% | -5% | 73% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 7 | 16 | 27 | 55 | 113 | 359 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KNSA | |
|---|---|---|---|---|
| KNSA | 122.5% | 44.2% | 1.94 | - |
| Sector ETF (XLV) | 9.9% | 17.4% | 0.38 | 27.4% |
| Equity (SPY) | 16.5% | 19.4% | 0.66 | 20.5% |
| Gold (GLD) | 81.3% | 25.7% | 2.29 | 4.1% |
| Commodities (DBC) | 13.4% | 16.9% | 0.58 | 2.2% |
| Real Estate (VNQ) | 7.3% | 16.6% | 0.25 | 26.8% |
| Bitcoin (BTCUSD) | -22.0% | 44.9% | -0.42 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KNSA | |
|---|---|---|---|---|
| KNSA | 13.4% | 53.3% | 0.43 | - |
| Sector ETF (XLV) | 8.7% | 14.5% | 0.41 | 25.5% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 26.1% |
| Gold (GLD) | 23.5% | 17.1% | 1.12 | 5.3% |
| Commodities (DBC) | 10.6% | 19.0% | 0.44 | 1.2% |
| Real Estate (VNQ) | 5.1% | 18.8% | 0.18 | 21.9% |
| Bitcoin (BTCUSD) | 4.0% | 57.0% | 0.29 | 12.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KNSA | |
|---|---|---|---|---|
| KNSA | 8.4% | 63.9% | 0.43 | - |
| Sector ETF (XLV) | 11.1% | 16.5% | 0.56 | 28.2% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 28.4% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 2.0% |
| Commodities (DBC) | 8.7% | 17.6% | 0.41 | 10.6% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | 22.8% |
| Bitcoin (BTCUSD) | 65.8% | 66.8% | 1.05 | 10.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/12/2026 | -6.1% | ||
| 10/28/2025 | -2.9% | -7.7% | 5.2% |
| 7/29/2025 | 12.3% | 21.9% | 24.1% |
| 4/29/2025 | 20.5% | 29.4% | 27.0% |
| 1/13/2025 | -8.8% | -7.0% | -1.2% |
| 10/29/2024 | -15.7% | -22.1% | -20.1% |
| 7/23/2024 | 22.9% | 22.2% | 23.1% |
| 2/28/2024 | -2.5% | -3.4% | -4.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 11 |
| # Negative | 12 | 12 | 11 |
| Median Positive | 12.1% | 24.2% | 20.7% |
| Median Negative | -4.0% | -6.6% | -17.9% |
| Max Positive | 30.4% | 41.8% | 47.4% |
| Max Negative | -15.7% | -22.1% | -22.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 10/29/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tessari, Eben | CHIEF OPERATING OFFICER | Direct | Sell | 12172025 | 41.56 | 12,048 | 500,715 | 692,639 | Form |
| 2 | Quart, Barry D | Direct | Sell | 12172025 | 41.51 | 20,129 | 835,555 | 520,784 | Form | |
| 3 | Ragosa, Mark | CHIEF FINANCIAL OFFICER | Direct | Sell | 12102025 | 41.49 | 42,841 | 1,777,473 | 1,289,758 | Form |
| 4 | Tessari, Eben | CHIEF OPERATING OFFICER | Direct | Sell | 12012025 | 42.89 | 200 | 8,578 | 974,203 | Form |
| 5 | Tessari, Eben | CHIEF OPERATING OFFICER | Direct | Sell | 11192025 | 41.24 | 12,470 | 514,224 | 936,655 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.